Galapagos listed 10 years on Euronext Amsterdam and Brussels
06 May 2015 - 3:31PM
Mechelen,
Belgium; 6 May 2015: Galapagos NV (Euronext: GLPG)
rings the opening bell today at Euronext
Amsterdam to celebrate 10 years as a listed company.
Ten years ago, on 5 May 2005,
Galapagos completed its initial public offering with a dual listing
in Amsterdam and Brussels. Since then, Galapagos has grown
from 70 to over 400 employees and from €70 million to around €1.2
billion in market capitalization. Galapagos forms part of the
Brussels BelMid Index and the Amsterdam Midcap Index.
Galapagos recently reported positive results with its JAK1
inhibitor filgotinib in the DARWIN 1 and DARWIN 2 trials in nearly
900 rheumatoid arthritis patients worldwide; this was one of the
research programs co-funded by the IPO in 2005.
About
Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action, with a
pipeline comprising three Phase 2 programs, two Phase 1 trials,
five pre-clinical studies, and 25 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed a collaboration agreement for the development and
commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos reported good activity and a favorable
safety profile at 12 weeks in both the DARWIN 1 and 2 trials in
RA. AbbVie and Galapagos also signed a collaboration
agreement in cystic fibrosis to develop and commercialize molecules
that address mutations in the CFTR gene. Potentiator GLPG1837
is currently in a Phase 1 trial, and corrector GLPG2222 is at the
pre-clinical candidate stage. GLPG1205, a first-in-class
inhibitor of GPR84 and fully-owned by Galapagos, is currently being
tested in a Phase 2 proof-of-concept trial in ulcerative colitis
patients. GLPG1690, a fully proprietary, first-in-class
inhibitor of autotaxin, has shown favorable safety in a Phase 1
trial and is expected to enter Phase 2 in idiopathic pulmonary
fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications &
IR
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking
statements
This release may contain forward-looking
statements, including, without limitation, statements concerning
anticipated progress, objectives and expectations regarding the
commercial potential of our product candidates, intended product
development, clinical activity timing, and other objectives and
explanations, all of which involve certain risks and uncertainties.
These statements are often, but are not always, made through the
use of words or phrases such as "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could," "stands to," "continues," "we believe," "we intend," as
well as similar expressions. Such forward-looking statements
may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to
be materially different from any historic or future results,
financial conditions, performance or achievements expressed or
implied by such forward-looking statements. Among the factors that
may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities, regulatory approval requirements and
estimating the commercial potential of our product candidates.
Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based, unless required by law or
regulation.
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
HUG#1919059
Galapagos (LSE:GLPG)
Historical Stock Chart
From May 2024 to Jun 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2023 to Jun 2024